FIG 4 .

LMP1 and NF-κB regulate CD226 expression. (A) ChIP-seq of NF-κB transcription factors (RelA, RelB, cRel, and p52) and EBV nuclear antigens (EBNA2 and EBNA3C) at the CD226 locus. RNA-seq coverage at the CD226 locus is shown below from early-infected B cells and LCLs. (B) BL41 cells transduced with an LMP1-expressing retrovirus or mock transduced with an empty vector control and then assayed by flow cytometry for CD226 surface expression. (C) BL41 cells were transduced with tetracycline-responsive LMP1 and assayed for surface levels of CD226 and LMP1 expression by flow cytometry at 18-h intervals following treatment with tetracycline. (D) LCLs were sorted into low-, middle-, and high-ICAM-1-expressing populations using FACS. mRNA levels of CD226, LMP1, and NF-κB targets (TRAF1, ICAM-1, and c-FLIP) were determined by qRT-PCR from two independent experiments. Data are reported as means ± SD. (E) LCLs were treated with 5 μM IKKβ inhibitor IV and DMSO and then analyzed for CD226 RNA expression with qRT-PCR. Data are reported as means ± SD. (F) CD226 mRNA expression on GCB DLBCLs, ABC DLBCLs, and LCLs was determined using microarray analysis. *, P < 0.05; ***, P < 0.001.